On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Moves Forward in Developing As-Needed Treatment for Social Anxiety Disorder

  • Company signs a worldwide licensing agreement with Pherin Pharmaceuticals for the development and commercialization of a Phase 3-ready CNS drug candidate for as-needed treatment of social anxiety disorder
  • Untreated social anxiety disorder has a significant impact on a person’s overall quality of life
  • Clinical studies support the potential of PH94B to be a superior treatment alternative for SAD due to the demonstrated rapid onset of efficacy, route of administration, as-needed dosing convenience and excellent safety profile

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need. The company recently announced (http://ibn.fm/d4viI) that it has signed a license with Pherin Pharmaceuticals, Inc., a biopharmaceutical company focused on developing novel treatments for neuropsychiatric and neuroendocrine conditions, for exclusive worldwide rights of a Phase 3-ready CNS drug candidate for as-needed treatment of social anxiety disorder.

An estimated 15 million American adults are affected by social anxiety disorder, also called social phobia or SAD. It is the third most common psychiatric condition, following depression and substance use, and generally precedes other disorders. A person suffering from SAD may have unrealistic fears of one or more social or performance situations that may have a significant impact on the person’s employment, social activities and overall quality of life.

Antidepressants are a common treatment for SAD but have a slow onset that may take several weeks to work, have numerous side effects and must be taken consistently over a long period of time. At this time, there is no FDA-approved treatment that provides rapid relief.

VistaGen has acquired exclusive worldwide rights from Pherin to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed treatment of social anxiety disorder, to address this problem. In a news release, Shawn Singh, CEO of VTGN, stated, “We are excited to be working with Pherin’s innovative team to develop and commercialize this medically and socially impactful treatment. Our key objective for the PH94B program is to commence our initial pivotal Phase 3 clinical trial of PH94B nasal spray for SAD during the first half of 2019.”

The PH94B nasal spray utilizes Pherin’s first-in-class proprietary compounds called pherines. These synthetic neuroactive steroids engage chemosensory receptors inhibiting nerve circuits, mediating behavioral and physiological effects of anxiety. By engaging receptors in the nasal passage, pherines are rapidly effective in low quantities. The onset of results provides an excellent safety profile with greater patient convenience. Previous clinical trials of PH94B provided evidence of rapid (10-15 minutes) anxiety reduction of subjects with SAD and no adverse events with the nasal spray administration.

“This agreement provides a meaningful opportunity to continue our clinical progress and advance our mission to bring novel treatment alternatives to the many individuals affected with SAD,” added Dr. Louis Monti, executive vice president of Pherin, “Our prior clinical studies support the potential of PH94B to be a superior treatment alternative for SAD due to the demonstrated rapid onset of efficacy, route of administration, as-needed dosing convenience, and excellent safety profile compared to other existing therapeutic options which require chronic dosing and have concurrent side effects.”

VistaGen has also acquired an option from Pherin to license an additional CNS neuropsychiatry-focused product now in Phase 2 development.

For more information, visit the company’s website at www.VistaGen.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered